10X Genomics Hits New 52-Week High at $25.69, Showcasing Market Resilience

10X Genomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 25.69 on April 15, 2026. This achievement underscores the stock's notable performance over the past year, where it has recorded a gain of 14.29%. In comparison, the S&P 500 has shown a stronger performance with a 30.14% increase during the same period. Despite the positive movement in stock price, 10X Genomics remains a loss-making entity, as indicated by its non-applicable price-to-earnings ratio. The company has a market capitalization of USD 2,132 million and a price-to-book ratio of 2.68, reflecting its valuation relative to its net assets. The stock's journey from a 52-week low of USD 7.25 to its current high illustrates a significant recovery and growth trajectory. However, the company does not offer dividends, and its return on equity stands at -10.80%, indicating challenges in generating profit from its equity base.